TY! I agree, and I have a firm belief that it will not be a problem.
IMHO the seeming complexities involved are exactly the sort of strategic bread-and-butter work for MT & JC that underpins their commercialisation objectives. They would be right across this stuff. MT in particular was three steps ahead of us with that unexpected Amylyx meeting; probably remains two steps ahead of the best of us; and easily one step ahead of the rest of us mere mortals.
Unpacking the pipeline strategy, intrigues the investment analyst part of me - and there are plenty here more deeply intimate with biotech strategy -- and for me, the interplay between mechanism of action, and the price-setting aspects, were of special interest, but I await to hear the thoughts of others, to isolate their special viewpoint in this ... cheers, Ice
PAA Price at posting:
21.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)